Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.

Vadivel Parthsarathy, C Hogg, Peter Flatt, Finbarr O'Harte

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

AimsThis study investigated the chronic effects of twice daily administration of stable apelin analogues, apelin-13 amide and (pGlu)apelin-13 amide, on metabolic parameters in glucose intolerant and insulin resistant diet-induced obese (DIO) mice fed a high-fat diet for 150 days.Study Design & MethodsGroups of mice received twice daily (09:00 and 17:00 h) injections of saline vehicle, apelin-13 amide, (pGlu)apelin-13 amide or exendin-4(1–39) for 28 days (all at 25 nmol/kg). Energy intake, body weight, non-fasting blood glucose, plasma insulin, glucose tolerance, metabolic response to feeding and insulin sensitivity together with pancreatic hormone content and biochemical parameters such as lipids and total GLP-1 were monitored. Dual-energy X-ray absorptiometry (DXA) analysis and indirect calorimetry were also performed.ResultsAdministration of apelin-13 amide, (pGlu)apelin-13 amide or exendin-4 significantly decreased bodyweight, food intake, blood glucose and increased plasma insulin compared with high-fat fed saline treated controls (P <0.05 and P <0.001), Additionally, all peptide treated groups exhibited improved glucose tolerance (oral and ip), metabolic responses to feeding and associated insulin secretion. (pGlu)apelin-13 amide also significantly improved HbA1c and insulin sensitivity after 28 days. Both (pGlu)apelin-13 amide and exendin-4 increased bone mineral content and decreased respiratory exchange ratio (RER), whereas only (pGlu)apelin-13 amide increased energy expenditure. All treatment groups displayed reduced circulating triglycerides and increased GLP-1 concentrations, although only (pGlu)apelin-13 amide significantly reduced LDL-cholesterol, total body fat, and increased pancreatic insulin content.ConclusionThese data indicate the therapeutic potential of stable apelin-13 analogues with effects equivalent to or better than exendin-4.
Original languageEnglish
Pages (from-to)319-327
Number of pages9
JournalDiabetes Obesity and Metabolism
Volume20
Issue number2
Early online date20 Jul 2017
DOIs
Publication statusPublished - 22 Aug 2017

Keywords

  • Apelin
  • diabetes
  • high fat fed mice
  • analogue

Fingerprint Dive into the research topics of 'Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.'. Together they form a unique fingerprint.

  • Profiles

    No photo of Finbarr O'Harte

    Finbarr O'Harte

    Person: Academic

    Cite this